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Abstract 
Background: Guillain–Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presenta‑
tion. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain 
unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies target‑
ing peripheral nerve components in Guillain–Barré syndrome.
Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the Interna‑
tional GBS Outcome study by 11 different Spanish centres. The screening included testing for anti‑ganglioside anti‑
bodies, anti‑nodo/paranodal antibodies, immunocytochemistry on neuroblastoma‑derived human motor neurons 
and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We 
analysed the staining patterns of patients and controls. The prognostic value of anti‑ganglioside antibodies was also 
analysed.
Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were 
positive for, at least, one anti‑ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently 
than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences 
were observed in the proportion of patients reacting against neuroblastoma‑derived human motor neurons. Reactiv‑
ity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only 
detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed 
that IgG anti‑GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors.
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Background
Guillain–Barré syndrome (GBS) is an acute inflamma-
tory neuropathy with a heterogeneous presentation 
that includes diverse clinical variants [1–3]. Diagno-
sis is based on clinical criteria; diagnostic biomark-
ers are not available for most patients [4]. The exact 
immunopathogenic mechanisms of GBS are rela-
tively unknown, but it is considered a paradigmatic 
post-infectious autoimmune disease [5]. Diverse 
mechanisms, including humoral and cellular immune 
responses, autoantibodies and complement, activated 
macrophages and lymphocytes, have been implicated 
in GBS pathogenesis [6, 7].
Anti-ganglioside antibodies are detected in up to 
half of GBS patients. These autoantibodies arise via 
microbial molecular mimicry [8] and the associa-
tion of specific anti-ganglioside antibody reactivities 
and specific disease variants is well-established in the 
literature [9, 10], particularly the association of anti-
GM1 [11] and GQ1b [12] antibodies with the pure 
motor and Miller  Fisher syndrome  (MFS) variants of 
GBS, respectively. In addition, the presence of anti-
bodies targeting the GM1 [11] or GD1a [13, 14] gan-
gliosides has also been associated with GBS prognosis. 
Antibodies against nodal and paranodal proteins (neu-
rofascin 140/186 [15] -NF140/186-, neurofascin 155 
[16, 17] -NF155-, contactin-associated protein 1 [18, 
19]  -CASPR1-, and contactin 1 [19] -CNTN1-) have 
also been described in patients diagnosed of GBS. 
However, the target antigens remain unknown in a 
substantial proportion of GBS patients, particularly 
of the acute inflammatory demyelinating polyradicu-
loneuropathy (AIDP) variant, the most frequent in 
patients of European ancestry.
Considering the broad clinical and epidemiological 
spectrum of GBS, the diverse infectious triggers and 
the T-cell independent nature of the immune reaction 
leading to the appearance of autoantibodies [20], we 
hypothesized that a broad repertoire of autoantibod-
ies targeting diverse nerve components may be causing 
nerve pathology in GBS. This study aims to (1) screen 
for autoantibodies against known antigens; (2) screen 
for antibodies against human and rodent nerve cells 
and monkey nerve tissue; (3) describe the diversity of 
staining patterns and (4) perform clinical–immunolog-
ical correlations, in a well-characterized GBS cohort.
Materials and methods
Patients and controls
Serum samples from 100 GBS patients included in the 
Spanish cohort of the International GBS Outcome study 
(IGOS) [21] were used in this screening. The IGOS is a 
multicentre, prospective, observational cohort study that 
investigates factors that determine and predict the clini-
cal course, subtype and outcome of GBS [22];  including 
patients fulfilling diagnostic criteria of the National Insti-
tute of Neurological Disorders and Stroke (NINDS) [1] or 
Miller Fisher syndrome (MFS) and other variants of GBS 
[3, 23]. Patients from the Spanish cohort were enrolled 
between February 2013 and January 2020. All patients 
fulfilled diagnostic criteria for GBS and were included 
within 2 weeks from onset of weakness. Serum samples 
were aliquoted and stored at − 80 °C until needed. In 
this study, we used serum samples extracted at baseline. 
Sixty-two (62%) of the baseline samples analysed were 
collected before starting treatment.
Clinical variants were defined as sensorimotor, pure 
motor, pure sensory, Miller Fisher syndrome (MFS) and 
ataxic. Nerve conduction studies results were classified 
as acute inflammatory demyelinating polyneuropathy 
(AIDP), acute motor axonal neuropathy (AMAN), acute 
motor-sensory axonal neuropathy (AMSAN), equivo-
cal or normal. The outcome of all patients with GBS at 
6  months and 1  year from disease onset were assessed 
using the GBS disability score (GDS), a widely accepted 
system for evaluating the functional ability of patients 
[24]. Patients unable to walk independently (≥ 3) at 
6 months were defined as having a poor outcome in this 
study.
Additionally, serum samples from a control group 
(n = 90) including 45 healthy controls and 45 patients 
with other neuromuscular disorders [23 amyotrophic 
lateral sclerosis (ALS), 22 Charcot–Marie–Tooth (CMT)] 
were included.
Autoantibody screening protocol
Autoantibody screening experiments included anti-
ganglioside antibody detection with ELISA, nodo/para-
nodal (NF155, NF140, NF186, CNTN1 and CNTN1/
CASPR1 complex) antibody detection by ELISA and 
cell-based assays, immunocytochemistry using patient 
sera on murine dorsal root ganglia (DRG) neurons and 
Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies target‑
ing nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic 
value; (3) further antigen‑discovery experiments may elucidate other potential antigens in GBS.
Keywords: Guillain–Barré syndrome (GBS), Autoantibodies, Anti‑ganglioside, Neurons, Prognosis
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neuroblastoma-derived human motor neurons (IgG and 
IgM) and reactivity pattern assessment by immunohis-
tochemistry on monkey sciatic nerve sections (IgG and 
IgM).
Testing for nodo/paranodal antibodies
Autoantibodies against NF140, NF186, NF155, CNTN1 
and CASPR1 were tested by ELISA.
Maxisorb 96-well ELISA plates (Thermo Fisher Scien-
tific, NUNC, Denmark) were coated with 1 μg/ml human 
recombinant CNTN1 protein (Sino Biological Inc., Geor-
gia, USA), 1  μg/ml NF155 protein (Origene, Maryland, 
USA), 1  μg/ml NF140 protein (Sino Biological), 1  μg/
ml NF186 protein (Origene) or 5  μg/ml CASPR1 pro-
tein (R&Dsystems, MI, USA) overnight at 4  °C. Wells 
were blocked with 5% non-fat milk in PBS 0.1% Tween 
20 for 1 h, incubated with sera diluted 1/100 in blocking 
buffer for 1 h, and then incubated with peroxidase con-
jugated rabbit anti-human IgG secondary antibody (Inv-
itrogen, CA, USA) for 1  h at room temperature. ELISA 
was developed with tetramethylbenzidine solution (Bio-
legend, California, USA), and the reaction was stopped 
with 25% sulfuric acid. Optical density (OD) was meas-
ured at 450  nm in a Multiscan ELISA reader. Samples 
were considered positive by ELISA when they had a ΔOD 
higher than mean healthy control ΔOD plus two stand-
ard deviations.
Cell-based assays were used as previously described 
[25] as a second confirmatory technique for questionable 
cases. Briefly, mammalian expression vectors encoding 
human NF140, NF186, NF155, CNTN1 or CASPR1 were 
transfected into HEK293 cells using Lipofectamine 2000 
(Invitrogen). Cells were then fixed with 4% paraformal-
dehyde and blocked. ICC experiments were performed 
using patient’s sera and appropriate primary and second-
ary antibodies.
Testing for anti‑ganglioside antibodies
Patients’ sera were screened for the presence of anti-
ganglioside antibodies using a previously validated ELISA 
protocol [26] as the general detection method, and thin 
layer chromatography [27] for confirmatory experiments. 
Anti-ganglioside antibodies were considered positive at a 
1/1000 titre.
Rat dorsal root ganglia neurons immunocytochemistry
DRG were dissected from E16 rat embryos, dissociated 
and plated in glass  coverslips coated with laminin (Inv-
itrogen) and poly-d-lysine (Sigma, MO, USA). Cells were 
grown in neurobasal medium (Gibco BRL, NY, USA) 
supplemented with B27 (Gibco), Glutamax (Gibco) and 
nerve growth factor (NGF) (Invitrogen). After 24  h, 
cytosine arabinoside (ARA-C) (Sigma) and fluorouracil 
(5-FU) (Sigma) were added to the medium to remove 
fibroblasts. Then, medium was replaced every other day 
until reaching complete growth and differentiation of 
DRG neurons.
Live DRG neurons were incubated for 1 h with patients’ 
sera diluted 1/100 (for IgG experiments) or 1/40 (for IgM 
experiments) in culture medium at 37 °C. Cells were then 
fixed for 10  min with 4% PFA and incubated with sec-
ondary antibodies. Goat anti-human IgG or IgM AF488 
(Molecular probes, Oregon, USA) were used as second-
ary antibodies at 1/1000 concentration.
Coverslips were mounted with Vectashield with DAPI 
and fluorescence signal intensity was scored in a 0–3 
scale by two independent researchers. Images were 
obtained with an Olympus BX51 Fluorescence Micro-
scope (Olympus Corporation, Tokyo, Japan).
Human neuroblastoma‑derived neurons 
immunocytochemistry
SH-SY5Y cells were plated in glass  coverslips coated 
with laminin at 2.5 µg/ml (Invitrogen). Cells were grown 
in proliferation medium containing DMEM/F12 (1:1), 
fetal bovine serum (10%), l-glutamine (1%) and Sodium 
pyruvate (1%). After 24  h, proliferation medium was 
replaced by differentiation medium containing Neuroba-
sal (Gibco) supplemented with B27 (Gibco), Glutamax 
(Gibco), nerve growth factor (Invitrogen) and retinoic 
acid at 10 µM (Sigma). Then, medium was replaced every 
other day until full differentiation was achieved. On days 
5 or 6 of differentiation, cells were fixed for 15 min with 
paraformaldehyde 4%; and blocked with 5% normal goat 
serum in PBS; followed by incubation with patients’ sera 
at 1/40 (for IgM) or 1/100 (for IgG). To observe the cor-
rect differentiation of the cells we also incubated them 
with chicken anti-panNeurofascin mAb (R&Dsystems) 
at 1/200. Goat anti-chicken IgG AF594 and goat anti-
human IgG AF488 or goat anti-human IgM AF488 
(Molecular Probes) were used as secondary antibodies at 
1/1000 concentration.
Coverslips were mounted with Vectashield with DAPI 
and fluorescence signal intensity was scored in a 0–3 scale 
by two independent researchers. Images were obtained 
with an Olympus BX51 Fluorescence Microscope.
Peripheral nerve immunohistochemistry
Macaque peripheral nerve tissue slides (Inova Diagnos-
tics, Inc., San Diego, CA) were blocked with 5% normal 
goat serum in PBS; followed by incubation with patients’ 
sera at 1:10 (for IgM) or 1:20 (for IgG). Monkey-adsorbed 
goat anti-human IgG AF488 (Southern Biotech, Alabama, 
US) or goat anti-human IgM AF488 (Molecular Probes) 
were used as secondary antibodies at 1/500 concentra-
tion. Finally, slides were mounted with Fluoromount 
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medium (Sigma) and examined by two independent 
observers. Immunostaining patterns were analysed scor-
ing fluorescence signal intensity of each nerve struc-
ture in a 0–3 scale. The nerve structures analysed were: 
nodes or paranodes, myelin from small myelinated fibres, 
myelin from large myelinated fibres, Schwann cells from 
unmyelinated fibres, large-fibre axons, and small-fibre 
axons. Reactivity against other non-nerve structures 
(fibroblasts, connective tissue, vessels) was not consid-
ered in the analysis.
To further study the staining patterns, peripheral nerve 
tissue slides were coated with mouse anti-human CD56 
antibody (Becton Dickinson, New Jersey, USA) at 1:50 to 
stain non-myelinating Schwann cells (Remak bundles); 
or with rabbit anti-human S100 antibody (Abcam, Cam-
bridge, UK) at 1:50 to stain myelinating Schwann cells. 
Goat anti-mouse IgG AF594 (for CD56), and goat anti-
rabbit IgG AF594 (for S100) were used as secondary anti-
bodies at 1/500 concentration.
Images were acquired using Leica TSC SP5 confocal 
microscope.
Statistical analysis
Results were analysed by GraphPad Prism v8.0 (Graph-
Pad Software). Statistical comparison of proportions 
among groups was performed using contingency analy-
sis with the application of Chi-square and a two-tailed 
Fisher’s exact test, accepting an alpha-level < 0.05 for sta-
tistical significance. To represent the results and perform 
hierarchical clustering of the results heatmap diagrams 
using the Clustvis web tool were performed [28].
To investigate the association between anti-gangli-
oside antibodies and prognosis a multivariable logis-
tic regression analysis to predict the inability to walk at 
6 months and at 1 year of follow-up (GDS ≥ 3) was per-
formed using the STATA software. A stepwise backward 
regression modelling to select variables independently 
associated with the outcome was performed first. The 
variables introduced in our initial multivariable models 
were selected based on known prognostic factors: age, 
initial GDS, diarrhoea, AMAN, serum NfL levels (ana-
lysed in a previous study with the same cohort) [29], 
serum anti-GM1 IgG antibodies and serum anti-GD1a 
IgG antibodies [29–32]. To perform the multivariable 
analysis patients with MFS were excluded, because our 
aim was to predict GBS prognosis and MFS is considered 
a different disease, including different pathophysiology, 
clinical presentation (it does not present with weakness), 
treatment (often untreated) and outcome (considered 
self-limiting and benign). Finally, the ability of the vari-
able “presence of anti-GM1 IgG antibodies” to predict 
the inability to run at 1 year of follow-up (GDS ≥ 2) was 
evaluated in our previously reported multivariable logis-
tic regression analysis [29].
Odds-ratios (OR) for the logistic regression analy-




We included 100 participants from 11 Spanish cen-
tres participating in the IGOS study. GBS patients had 
an average of 57.4  years and were predominantly men 
(57%). 65% of patients presented with the sensorimotor 
variant, 19% presented with the pure motor GBS variant, 
10% with MFS, 5% with the pure sensory variant and 1 
patient with the ataxic variant. Regarding nerve con-
duction studies, 59% of patients were classified as AIDP, 
12% as AMAN, 7% as AMSAN, 8% as normal, and 14% 
as equivocal. Detailed epidemiological features of the 
cohort were described elsewhere [29].
Screening for known autoantibodies
None of the GBS patients included in the study reacted 
against the paranodal and nodal proteins tested (NF155, 
NF140, NF186, CNTN1 and CASPR1).
Sixty-one patients tested positive for, at least, one anti-
ganglioside antibody (GM1, GM2, GM3, GD1b, GD3, 
aGM1, GT1a, GT1b and GQ1b). Of these, 40 had IgG 
antibodies, 3 had IgM antibodies, and 18 had antibodies 
from both isotypes. Detailed anti-ganglioside reactivities 
are shown in Additional file 1.
Most frequent anti-ganglioside antibodies in our 
cohort were aGM1, GM1, GD1b and GQ1b. Overall, IgG 
anti-aGM1 antibodies were detected in 40% of patients; 
IgG and IgM anti-GM1 antibodies were detected in 27% 
and 15% of patients, respectively, IgG anti-GD1b anti-
bodies in 30%, and IgG anti-GQ1b antibodies in 21% 
patients.
Antibodies targeting peripheral nerve neurons
ICC experiments with primary cultures of rat DRG neu-
rons and human motor neurons derived from a neuro-
blastoma cell line were used to identify novel IgG and 
IgM reactivities against peripheral nerve neurons. The 
screening was performed in 100 serum samples from 
GBS patients and 90 serum samples from a control 
group (including healthy controls and patients with other 
neuromuscular diseases). ICC results were grouped in 
three separate categories: moderate-to-strong positives 
(including scores 2 and 3), all positives (including scores 
1, 2 and 3), and negatives (score 0).  Detailed results are 
shown in Additional file 2, Fig. 1 and Table 1.
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Overall, 22 (22%) GBS patients reacted moder-
ately or strongly against DRG or neuroblastoma 
neurons, whereas 4 (4.4%) controls reacted only mod-
erately. These differences were statistically significant 
(p = 0.0005).
Antibodies against DRG neurons appeared significantly 
more frequently in GBS patients than in controls (32% vs 
6.7%, p < 0.0001) taking all positive tests in account; the 
same happened if only moderate and strong positives 
were considered, both in IgG (6% vs 0%, p = 0.03) and 
IgM experiments (11% vs 2.2%, p = 0.02).
In neuroblastoma-derived neuron ICC experiments 28 
(28%) samples from the GBS group showed IgM autoan-
tibodies; of these 8 (8%) showed moderate or strong 
reactivity. These proportions were significantly higher 
than in the control group (12.2% and 2.2%, respectively; 
p = 0.011). Differences in autoantibody proportions 
between GBS patients and controls were not observed 
Fig. 1 Reactivity against rat DRG neurons and human neuroblastoma‑derived neurons. DRG neurons (A, B) stained with a GBS patient’s serum 
reacting moderately (score 2) in IgG (A), and a GBS patient’s serum reacting strongly (score 3) in IgM (B). Human neuroblastoma‑derived neurons 
(C, D) stained in red with anti‑panNeurofascin mAb, and in green with a GBS patient’s serum reacting moderately (score 2) in IgG (C) and a GBS 
patient’s serum reacting strongly (score 3) in IgM (D)
Table 1 Statistical analysis of DRG and neuroblastoma neurons ICC, and monkey peripheral nerve IHC
Comparison between GBS patients and controls. Strong reactivity includes scores 2 and 3, and any reactivity includes scores 1, 2 and 3. Fluorescence intensity scores 
were analysed using contingency analysis with the application of a Fisher’s exact test, accepting an alpha-level of < 0.05 to determine significance
GBS patients (n = 100) Controls (n = 90/56) p value
Any reactivity Strong reactivity Any reactivity Strong reactivity Any reactivity Strong reactivity
Neuroblastoma neurons IgG 11 (11%) 2 (2%) 10/90 (11.1%) 0/90 (0.0%)  > 0.999 (ns) 0.499 (ns)
Neuroblastoma neurons IgM 28 (28%) 8 (8%) 11/90 (12.2%) 2/90 (2.2%) 0.011 (*) 0.105 (ns)
DRG neurons IgG 32 (32%) 6 (6%) 6/90 (6.7%) 0/90 (0.0%)  < 0.0001 (***) 0.030 (*)
DRG neurons IgM 34 (34%) 11 (11%) 22/90 (24.4%) 2/90 (2.2%) 0.156 (ns) 0.020 (*)
Monkey peripheral nerve IgG 56 (56%) 17 (17%) 30/56 (53.6%) 3/56 (5.4%) 0.8669 (ns) 0.0455 (*)
Monkey peripheral nerve IgM 44 (44%) 10 (10%) 20/56 (35.7%) 6/56 (10.7%) 0.3964 (ns)  > 0.999 (ns)
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in neuroblastoma-derived neuron experiments when 
assessing IgG antibodies.
Antibodies targeting peripheral nerve tissue
We analysed the full GBS cohort and 56 controls.
We analysed the staining intensity of six different struc-
tures within the nerve, including nodes or paranodes, 
myelin from small myelinated fibres, myelin from large 
myelinated fibres, Schwann cells from unmyelinated 
fibres, large-fibre axons, and small-fibre axons. Staining 
patterns can be found in Additional file 3.
IgG and IgM reactivity against nerve tissue was fre-
quently detected in GBS patients and controls. Overall, 
about 70% of GBS patients and controls sera bound to 
nerve structures. IgG and IgM from GBS patients reacted 
moderately in 17 (17%) and strongly in 10 (10%) against 
monkey nerve structures. In the control group IgG and 
IgM reacted moderately in 8 (14.3%) and strongly in 1 
(1.8%) against monkey nerve structures. The difference 
between the amount of GBS patients and controls react-
ing moderately or strongly against monkey peripheral 
nerve was statistically significant (p = 0.0455) only for 
IgG autoantibodies (Table 1).
Differences in IHC patterns of reactivity from GBS 
patients and controls were not statistically significant 
for any of the structures analysed (Additional file  4). 
Nonetheless, some specific reactivity patterns were only 
detected in GBS patients and not in controls (Fig.  2). 
Eight (8%) GBS patients’ IgG reacted strongly against 
myelin, whereas only 2 controls showed weak reactiv-
ity against this structure. Moreover, we observed that 13 
(13%) GBS patients’ IgG had a strong reactivity against 
Schwann cells (myelinating and non-myelinating) while 
only one of the controls (1.8%) showed strong reactivity 
against Schwann cells (this difference is statistically sig-
nificant; p = 0.0192).
Combined autoantibody screening analysis
We also analysed if GBS patients with or without anti-
ganglioside antibodies differed in the reactivity patterns 
in the peripheral nerve cell and tissue autoantibody 
screening experiments. No differences were found 
between those two groups (Additional file  4), suggest-
ing that the heterogeneity of the autoantibody repertoire 
appears even when a specific antigen is found.
We used a heatmap graph to represent all the autoan-
tibody screening results performed in our GBS cohort 
(Fig. 3) [28]. This graph provides visual representation of 
the heterogeneity of the autoantibody repertoire in GBS 
sera.
Clinical correlations
Among patients with Miller Fisher syndrome, 8/10 (80%) 
had IgG anti-GQ1b antibodies, whereas in the rest of 
GBS patients only 14.4% (13/90) had these antibod-
ies, usually in combination with other reactivities. IgG 
anti-GM1 antibodies were more frequently detected in 
patients with the pure motor variant than in those with 
other clinical variants [13/19 (68.4%) vs 14/81 (17.3%)]; 
and in patients classified electrophysiologically as AMAN 
than in the rest of GBS patients (83.3% vs 19.3%). All 
these differences were statistically significant (p < 0.0001).
Fig. 2 Reactivity against Schwann cells in peripheral nerve sections. Macaque peripheral nerve sections stained in red with S100 (A–D) or CD56 
(NCAM) monoclonal antibody (E–H), and in green with GBS patient’s sera reacting against myelin from small myelinated fibres (A, E), myelin from 
large myelinated fibres (B, F), and non‑myelinating Schwann cells (C, G). D and H are stained with sera from negative controls
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When we analysed the general clinical characteris-
tics of the subgroup of patients with strong IgG reactiv-
ity against Schwann cells (n = 13), we did not observe 
any specific pattern that could distinguish them from 
the rest of the cohort. Ten (76.9%) of these patients pre-
sented with the sensorimotor clinical variant, whereas 
in the general cohort 65% presented this variant; and 
the proportions of nerve conduction studies subgroups 
were similar to those found in the general cohort (53.8% 
vs 59% of AIDP electrophysiological variant). Regarding 
the outcome, the percentage of patients having a good 
outcome at 6  months and 1  year are similar in the two 
groups (about 75%).
In the subgroup of patients with IgG or IgM reactivity 
against DRG neurons (n = 14), we did not find clinical 
differences with the whole GBS cohort. Briefly, 71.4% of 
patients staining strongly DRG neurons were classified 
as AIDP, and 64.3% presented with the sensorimotor 
clinical variant.
We did not detect any difference in peripheral 
nerve cell and tissue reactivity patterns or frequen-
cies between the samples collected before starting the 
treatment (62%) and those collected after the treat-
ment (38%). We neither observed any correlation of 
Fig. 3 Heatmap showing all the screening performed in GBS patients. Patients and reactivities against anti‑ganglioside antibodies, 
neuroblastoma‑derived human motor neurons, murine dorsal root ganglia neurons and monkey peripheral nerve tissue, are ordered according 
to Euclidean clustering. Each row represents one GBS patient. The score of the anti‑ganglioside titre is indicated by the colour of the square 
(0 =  < 1/1000, 1 = 1/1000–1/2500, 2 = 1/2500–1/12500, 3 =  > 1/12500). The score of staining intensity in the other structures is indicated by the 
colour of the square (0 = negative, 1 = mild positive, 2 = moderate positive, 3 = strong positive). Columns in the left contain information related to 
the clinical variant and the outcome at 6 months and at 1 year of follow‑up
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any of the reactivity patterns with other clinical char-
acteristics as pain, ataxia, or the presence of antecedent 
infection.
Prognostic value of anti‑ganglioside antibodies
First, we conducted a univariate analysis to select varia-
bles that were associated with the outcome. Patients with 
serum IgG anti-GM1 antibodies presented poorer out-
comes than patients without the antibodies at 6 months 
[38.1% vs 16.1% (p = 0.04)], and 1  year [35.3% vs 9.7% 
(p = 0.014)]. Anti-GD1a IgG antibodies were not associ-
ated with prognosis (Table 2). For the multivariate analy-
sis, we included GM1 IgG, serum NfL levels, diarrhoea, 
age, and initial GDS.
We observed that having anti-GM1 IgG antibodies at 
baseline was independently associated with the inability 
to walk at 1 year of follow-up, after a backward stepwise 
selection modelling (OR 6.98, 95% CI 1.6–30.36; p = 0.01). 
However, the presence of anti-GM1 IgG antibodies was 
not independently associated with having a poor out-
come at 6 months (Table 2).
To analyse if anti-GM1 titres were associated with the 
GBS disability score, we performed a linear regression. 
We did not observe a positive correlation between anti-
body titres and disability at 6 months and at 1 year.
Finally, when we included the presence of anti-GM1 
antibodies in our previously reported prognostic study 
[29], we observed that having anti-GM1 IgG antibodies at 
baseline was associated with the inability to run at 1 year, 
but this association was not independent from the other 
known prognostic factors and sNfL, age and AMAN 
remained in the model as independent factors associated 
with residual disability at 1 year.
Discussion
Our work describes a comprehensive autoantibody 
screening that provides experimental evidence of the het-
erogeneity of the autoantibody repertoire in patients ful-
filling GBS diagnostic criteria.
Our study shows that GBS patients have a heteroge-
neous repertoire of autoantibodies targeting nerve cells 
and structures. Except for patients with anti-ganglioside 
antibodies and a minor subset of patients with antibodies 
targeting Schwann cells and the myelin sheath, this rep-
ertoire varies in frequency and intensity of staining, but 
it is not qualitatively different from controls. Antibodies 
targeting peripheral nerve cells of both IgG and IgM iso-
types are significantly more frequent in patients than in 
controls, but no clear differences are seen when antibod-
ies are tested using immunohistochemistry on monkey 
nerve preparations. Considering that whole nerve mon-
key preparations likely display protein antigens in a con-
formation that is phylogenetically closer to that of human 
nerves, this may imply that autoantibodies targeting 
nerve structures are present in normal human repertoire 
at lower titers, that they arise as a natural epiphenome-
non of a T-cell mediated damage and are not pathogenic, 
or that other autoantibodies, targeting different types of 
molecules (such as lipids or glycans), for which our tech-
niques are not optimized, are yet to be discovered.
Whether these autoantibodies arise from a process of 
molecular mimicry, or from an unspecific and polyclonal 
activation of pre-existing B cells, remains unclear. The 
general absence of common patterns suggests the lat-
ter, but the well-established molecular mimicry process 
described in anti-ganglioside-associated GBS supports 
the former. In anti-GM1-associated GBS the sequence 
of pathogenic events includes an immune response 
to an infection leading to the appearance of antibod-
ies cross-reacting with peripheral nerve and nerve root 
gangliosides and triggering post-infectious inflamma-
tion [33]. Interestingly, in this screening we did not find 
clear differences in the reactivity patterns between GBS 
patients with or without anti-ganglioside antibodies, but 
we observed in both groups a higher amount of patients 
staining nerve structures than in controls. These find-
ings suggest that the immune response in GBS is not 
restricted to the production of anti-ganglioside anti-
bodies, but it is also targeting other peripheral nerve 
structures. This observation may either reflect the pres-
ence of a polyclonal, not antigen-driven, reactivation of 
a pre-existing repertoire that, in some patients, includes 
gangliosides, or the concomitant activation (by epitope 
spreading or bystander activation) of unspecific B cells 
in addition to the ganglioside-driven antigen-specific 
response.
Previous studies in other inflammatory neuropathies 
such as chronic inflammatory demyelinating polyneurop-
athy (CIDP), showed that frequencies of reactivity against 
DRG neurons in CIDP patients did not differ from 
healthy controls [34], in contrast with our results (shown 
in Table  2). GBS and CIDP are similar diseases both 
clinically and electrophysiologically, so this difference 
supports the idea that a heterogeneous autoantibody 
response against multiple nerve antigens arises in GBS 
while this does not happen in chronic inflammatory and 
demyelinating neuropathies in which a specific, antigen-
driven autoantibody response arises, as the recent dis-
covery of the nodo-paranodal antibodies supports [35]. 
Differences in severity of these two diseases may also 
account for this observation.
We observed that 13% of GBS patients showed 
strong IgG reactivity against Schwann cells of mon-
key peripheral nerve. This observation is in agree-
ment with previous findings: Kwa et  al. observed 
that 24% of GBS patients had IgG antibodies against 
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non-myelinating human Schwann cells [36], and Val-
lat et  al. also detected that a significant percentage of 
CIDP and GBS patients (about 25%) presented with IgG 
or IgM reactivity against myelin and that the staining 
patterns on Schwann cells were diverse, suggesting that 
diverse myelin antigens are being recognized by the 
autoantibodies [37].
Our study also confirms, in a well-characterized GBS 
cohort, that gangliosides are the most frequent spe-
cific antigens in GBS patients and that they associate 
to specific disease variants. The value of testing anti-
ganglioside antibodies in the GBS routine clinical care 
is controversial, but it is clear that some antibodies are 
associated with specific clinical phenotypes [38]. IgG 
anti-GQ1b antibody is a diagnostic marker and a patho-
genic antibody in MFS, and is often cross-reactive with 
GT1a [9]. Moreover, IgG anti-GM1 antibodies associate 
with the pure motor (clinical) and AMAN (electrophysi-
ological) variants. Our results, with 80% of MFS patients 
having anti-GQ1b antibodies and 68.4% of pure motor 
patients having anti-GM1 antibodies at baseline, con-
firm these associations. However, our study lacks power 
to find other potential associations previously described 
(anti-GD1b with acute ataxic neuropathy, anti-GT1a and 
pharyngo-cervico-brachial variant) [39, 40] that will need 
to be confirmed in even larger cohorts. Likewise, the 
clinical relevance of antibodies targeting other structures 
(neurons, peripheral nerve tissue…) is unclear, since their 
association with GBS is not completely specific or the 
number of patients with each particular reactivity is too 
low to draw any conclusions.
Some studies have reported a correlation between IgG 
anti-GM1 and anti-GD1a antibodies with a poor out-
come in GBS patients [13, 14, 33, 41]. In our cohort, IgG 
anti-GD1a antibodies did not associate to a poor out-
come of the disease [13]. However, our data confirm that 
IgG anti-GM1 antibody is an independent prognostic fac-
tor that associates with poor prognosis at 1 year, support-
ing that it may be a marker for long-term axonal damage. 
Whether the presence of complement-fixing anti-GM1 
antibodies is the driver of this long-term disability, an 
important therapeutic question (that would enable the 
use of complement inhibitors in these patients), remains 
to be elucidated.
Although in this study we analysed the prognostic 
value of anti-ganglioside antibodies using the tradi-
tional outcome measures: inability to walk (GDS ≥ 3) at 
6 months and at 1 year, we have recently used the inabil-
ity to run (GDS ≥ 2) as a measure of the presence of long-
term residual disability. In this recent study we showed 
that high baseline sNfL were independently associated 
with inability to run at 1  year [29]. In agreement with 
these findings, we observed that including in the model 
the variable “presence of serum IgG anti-GM1 antibod-
ies”, sNfL levels remained as an independent prognos-
tic factor, whereas anti-GM1 antibodies did not. These 
results confirm that sNfL levels are a prognostic factor 
that informs better on axon status and, consequently, on 
long-lasting disability.
It is interesting to note that we did not find any 
patient with anti-nodal/paranodal antibodies (CNTN1, 
NF140, NF186, NF155 and CASPR1) in our GBS cohort. 
Although previous studies from other authors have found 
some GBS positive patients in their cohorts [14–18], and 
case-reports and series describe the association of anti-
nodal/paranodal antibodies with aggressive inflamma-
tory neuropathies frequently misdiagnosed as GBS, these 
antibodies are rare and we cannot rule out the possibility 
that they are present in other selected patients that our 
cohort failed to capture.
One of the limitations of our study is the number of 
patients and controls included. We have small groups 
of patients with similar staining patterns in which it is 
difficult to establish clear clinical-immunological cor-
relations. Nevertheless, this is the first large prospec-
tive study assessing the autoantibody repertoire against 
peripheral nerve structures in GBS patients and antigen-
identification experiments will follow in those patients 
showing specific staining patterns that are absent in 
controls.
The existence of clear subgroups associated with anti-
ganglioside antibodies, in contrast with the diversity in 
the new reactivities analysed, suggests that this appar-
ent heterogeneity may be also due to technical caveats, 
because our study protocol is optimized for proteins and 
not for lipids or glycans. Moreover, other, not properly 
controlled factors, could have influenced heterogeneity in 
staining patterns (treatment, comorbidities…), and will 
need to be assessed in larger cohorts.
Conclusions
In conclusion, our study highlights the heterogeneity of 
the profile of autoantibodies targeting peripheral nerve 
structures, confirms gangliosides as the most frequent 
target antigens in the GBS autoantibody repertoire and 
their prognostic value in long-term GBS prognosis, and 
identifies small subsets of GBS patients with specific 
staining patterns in which further antigen-identification 
experiments could demonstrate novel and clinically rel-
evant autoantibody reactivities in the future.
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was scored in a 0–3 scale (0 = negative, 1 = mild positive, 2 = moderate 
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